XML 46 R33.htm IDEA: XBRL DOCUMENT v3.24.4
Patent and Technology License Agreements (Details) - USD ($)
 1 Months Ended 12 Months Ended
Oct. 06, 2020
Jan. 31, 2023
Jan. 31, 2022
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2021
Patent and Technology License Agreements [Line Items]            
Annual maintenance fee   $ 75,000 $ 60,000      
Research and development       $ 11,906,601 $ 14,819,729  
Upfront payment       250,000    
Milestone fees       33,700,000    
Patent and Technology License Agreement – Mino-Lok [Member]            
Patent and Technology License Agreements [Line Items]            
Fee expense       90,000 $ 90,000  
Annual minimum royalty payment       100,000    
Increasing annual royalties       25,000    
Payable amount to NAT       1,100,000    
Patent and Technology License Agreement – Mino-Lok [Member] | Maximum [Member]            
Patent and Technology License Agreements [Line Items]            
Increasing annual royalties       150,000    
Patent and Technology License Agreement – Mino-Wrap [Member]            
Patent and Technology License Agreements [Line Items]            
Annual minimum royalty payment       100,000    
Increasing annual royalties       15,000    
Development milestone payments       2,100,000    
Patent and Technology License Agreement – Mino-Wrap [Member] | Maximum [Member]            
Patent and Technology License Agreements [Line Items]            
Annual minimum royalty payment       25,000    
Increasing annual royalties       90,000    
License Agreement Eterna [Member]            
Patent and Technology License Agreements [Line Items]            
Obligated pay amount       $ 51,000,000    
Revenue percentage       50.00%    
License Agreement Eterna [Member] | NoveCite [Member]            
Patent and Technology License Agreements [Line Items]            
Minority equity interest 25.00%          
License Agreement with Eisai [Member]            
Patent and Technology License Agreements [Line Items]            
Research and development       $ 33,700,000    
Upfront payment       40,000,000    
Commercial sales milestones       $ 300,000,000    
Net sales percentage       50.00%    
Paying an extension fee       $ 10,000,000    
Milestone fees       $ 5,000,000    
License Agreement with Eisai [Member] | License Agreement [Member]            
Patent and Technology License Agreements [Line Items]            
License agreement development, description       Under the license agreement, Eisai is to receive a $5.9 million development milestone payment upon initial approval and additional commercial milestone payments related to the achievement of net product sales thresholds (which increases to $6.9 million in the event we have exercised our option to add India to the licensed territory prior to FDA approval) and an aggregate of up to $22 million related to the achievement of net product sales thresholds. We also were required to reimburse Eisai for up to $2.65 million of its costs to complete the ongoing Phase 3 pivotal clinical trial for LYMPHIR for the CTCL indication and reimburse Eisai for all reasonable costs associated with the preparation of a Biologics License Application (“BLA”) for LYMPHIR.    
License Agreement with Eisai [Member] | Maximum [Member]            
Patent and Technology License Agreements [Line Items]            
Development milestone payments       $ 70,000,000    
License Agreement with Eisai [Member] | Dr. Reddy’s Laboratories, Ltd [Member]            
Patent and Technology License Agreements [Line Items]            
Development milestone payments       $ 40,000,000    
NoveCite [Member] | License Agreement Eterna [Member]            
Patent and Technology License Agreements [Line Items]            
Research and development           $ 5,000,000
Percentage of ownership additional shares 25.00%          
License Agreement [Member] | License Agreement Eterna [Member]            
Patent and Technology License Agreements [Line Items]            
Outstanding equity 75.00%